Reviva Pharmaceuticals Holdings, Inc.: 10-Q filed 2022-11-14
What Reviva Pharmaceuticals Holdings, Inc. reported in its quarterly report filed 2022-11-14 (fiscal Q3 2022): 24 published measures, 72 facts as tagged in accession 0001437749-22-027265.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-11-14
- Fiscal period
- fiscal Q3 2022
- Accession
- 0001437749-22-027265 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Reviva Pharmaceuticals Holdings, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 24,040,950 | USD | |
| At 2021-12-31 | 31,404,001 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 3,681,431 | USD | |
| At 2021-12-31 | 2,717,541 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 20,359,519 | USD | |
| At 2022-06-30 | 16,060,380 | USD | |
| At 2021-12-31 | 28,686,460 | USD | |
| At 2021-09-30 | 32,269,346 | USD | |
| At 2021-06-30 | 34,520,972 | USD | |
| At 2020-12-31 | 5,465,750 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 23,191,927 | USD | |
| At 2021-12-31 | 29,687,944 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -3,515,308 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -16,221,020 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -2,279,216 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -4,836,923 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | -14,269,947 | USD | 273 |
| 2021-01-01 to 2021-09-30 | -6,766,309 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 7,773,930 | USD | 273 |
| 2021-01-01 to 2021-09-30 | 31,497,463 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | -83,052,989 | USD | |
| At 2021-12-31 | -66,831,969 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 19,269,989 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 18,737,330 | shares | 273 |
| 2021-07-01 to 2021-09-30 | 18,455,586 | shares | 92 |
| 2021-01-01 to 2021-09-30 | 13,554,548 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -0.18 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.87 | USD/shares | 273 |
| 2021-07-01 to 2021-09-30 | -0.12 | USD/shares | 92 |
| 2021-01-01 to 2021-09-30 | -0.36 | USD/shares | 273 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 1,864 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 12,414 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 2,102 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 6,004 | USD | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 120,149 | USD | 273 |
| 2021-01-01 to 2021-09-30 | 44,679 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -3,562,953 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -16,532,598 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -2,476,840 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -6,139,870 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 3,575,732 | USD | |
| At 2021-12-31 | 2,344,811 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 2,347,798 | USD | |
| At 2021-12-31 | 509,583 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 3,562,953 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 16,532,598 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 2,476,840 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 6,139,870 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 2,305,981 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 12,650,388 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 1,423,359 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 2,188,849 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 20,442,871 | shares | |
| At 2021-12-31 | 14,433,286 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 103,410,464 | USD | |
| At 2021-12-31 | 95,516,986 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 849,023 | USD | |
| At 2021-12-31 | 1,716,057 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -3,513,444 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -16,208,606 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -2,277,114 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -4,830,919 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 1,256,972 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 3,882,210 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 1,053,481 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 3,951,021 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 49,509 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 323,992 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 199,726 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 1,308,951 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 1,630,662 | USD | 273 |
| 2021-01-01 to 2021-09-30 | -587,263 | USD | 273 |
Inspect the source
- Entity
- Reviva Pharmaceuticals Holdings, Inc. / CIK 0001742927
- Captured
- 2026-09-19T11:20:56.685Z
- SEC response SHA-256
26f740ff1a169faebcba46f28197dc15a1be7bab2feb9b4952e7b7f15df066e6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001742927.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))